Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: SGLT2i, Topics May 11 | 2017Lexicon announces additional Ph3 sotagliflozin results in T1DMPurchase Blast
$599
Posted in: Bolus Insulin, Glucose Monitoring, Topics May 04 | 2017Mannkind and One Drop enter collaboration for better diabetes outcomesPurchase Blast
$599
Posted in: Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, SGLT2i, Topics Apr 25 | 2017Lilly Q1 ’17 Earnings UpdatePurchase Blast
$599
Posted in: DPP-IVi, Other, SGLT2i, Topics Apr 19 | 2017Lilly Initiates Ph1 for New OADPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, SGLT2i, Topics Apr 18 | 2017J&J Q1 ’17 Earnings UpdatePurchase Blast
$599
Posted in: SGLT2i, Topics Apr 12 | 2017Invokana CKD Outcomes Trial (CREDENCE) Primary Completion Date DelayedPurchase Blast
$599
Posted in: DPP-IVi, Topics Apr 07 | 2017Merck’s Januvia Receives CRL from FDA for TECOSPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, SGLT2i, Topics Mar 24 | 2017Lilly Increases Diabetes Manufacturing Investment in 2017Purchase Blast
$599
Posted in: GLP-1RA, GLP-1RA + Basal, SGLT2i, Topics Mar 23 | 2017Lilly Partners with Sansum for Diabetes Research in the Latino PopulationPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Topics Mar 01 | 2017Mylan Q4 ’16 Earnings and Investor Day UpdatePurchase Blast
$599
Posted in: DPP-IVi, SGLT2i, Topics Mar 01 | 2017Merck/Pfizer Filed Ertugliflozin and FDCs in December 2016Purchase Blast
$599
Posted in: SGLT2i, Topics Feb 17 | 2017Lexicon Presentation at Leerink Healthcare ConferencePurchase Blast
$599
Posted in: SGLT2i, Topics Feb 16 | 2017J&J’s Invokana Receives Toe Amputation Warning from EMAPurchase Blast
Get the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
